Jennifer Robinson
Investor Relations Contact at VERVE THERAPEUTICS, INC.
Profile
Jennifer Robinson is currently the Vice President of Investor Relations & Communications at Verve Therapeutics, Inc. Prior to her current position, she worked as the Senior Director of Investor Relations at Dyax Corp.
from 2014 to 2016, and as the Senior Director of Investor Relations at Ra Pharmaceuticals, Inc. and resTORbio, Inc. She also served as the Vice President of Investor Relations & Communications at Deciphera Pharmaceuticals, Inc. Ms. Robinson received her undergraduate degree from Dartmouth College.
Jennifer Robinson active positions
| Companies | Position | Start |
|---|---|---|
| VERVE THERAPEUTICS, INC. | Investor Relations Contact | - |
Former positions of Jennifer Robinson
| Companies | Position | End |
|---|---|---|
| DYAX CORP. | Investor Relations Contact | 2016-03-31 |
| RA PHARMACEUTICALS, INC. | Investor Relations Contact | - |
| DECIPHERA PHARMACEUTICALS, INC. | Investor Relations Contact | - |
| ADICET BIO, INC. | Investor Relations Contact | - |
Training of Jennifer Robinson
| Dartmouth College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| DECIPHERA PHARMACEUTICALS, INC. | Health Technology |
| VERVE THERAPEUTICS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Dyax Corp.
 Dyax Corp. Pharmaceuticals: MajorHealth Technology Dyax Corp. engages in discovery, development and commercialization of novel biotherapeutics. The company was founded by Henry E. Blair in 1989 and is headquartered in Burlington, MA. | Health Technology |
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of peptide-based drugs. It uses Extreme Diversity platform that allows to produce synthetic macrocyclic peptides. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA. | Health Technology |
resTORbio, Inc.
 resTORbio, Inc. BiotechnologyHealth Technology resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Jennifer Robinson
